This multinational , randomized , double-blind , parallel group phase III study ( NCT01339260 ) in 1455 chemotherapy-nave patients receiving moderately emetogenic ( anthracycline-cyclophosphamide ) chemotherapy evaluated the efficacy and safety of a single oral dose of NEPA versus a single oral dose ( 0.50 mg ) of PALO .